Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. We report an updat...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Cancer J
Main Authors: Kaufman, Jonathan L., Dimopoulos, Meletios A., White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Joy Ho, P., Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Sutherland, Heather J., Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Miles Prince, H., Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J., Chari, Ajai, O’Rourke, Lisa, Trivedi, Sonali, Casneuf, Tineke, Krevvata, Maria, Ukropec, Jon, Kobos, Rachel, Avet-Loiseau, Hervé, Usmani, Saad Z., San-Miguel, Jesus
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group UK 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7643179/
https://ncbi.nlm.nih.gov/pubmed/33149130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-00375-2
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker